Early Access To Santheras Dmd Therapy Raxone Extended In The Uk - Latest News

Early access to Santhera’s DMD therapy Raxone extended in the UK

UK regulators have renewed the scientific opinion for Santhera’s Raxone, extending its availability to patients with Duchenne muscular dystrophy (DMD) through the Early Access to Medicines Scheme (EAM... read more

Santhera facing long delay for muscular dystrophy drug in US

Santhera is facing a considerable delay in the US before it can get approval for Duchenne muscular dystrophy (DMD) candidate Raxone ... access to new therapies for the disease. In recent months the FD... read more

BioMarin files muscular dystrophy drug in EU

At the moment the only approved therapy ... Raxone/Catena (idebenone) candidate has completed phase III testing. Unlike its rivals Sathera's drug - an antioxidant - specifically targets respiratory dy... read more